" Now, top pharma companies will be looking at the next wave of combinations of immunotherapies, in which ilixadencel is strongly positioned with a highly complementary mechanism of action, excellent safety profile and advanced stage of development, with over 90 patients already treated. We believe ilixadencel’s position as a potential backbone therapy to both targeted therapies and checkpoint inhibitors can take the center stage as the Phase II MERECA and Phase Ib/II ILIAD studies start reading out in 2019 and onwards."
The Phase II MERECA study in renal cancer will be a great trigger in Q3 2019 when the results will become official. The Phase I/II-study (11 patients) in renal cancer was very promising with overall median survival 48 months with ilixadencel + standard treatment compared with 15-16 months according to the litterature with just standard treatment.
Immunicum will have a market capital of around USD 86 million after having completed the current stock issue, and with clinical studies completed or ongoing in Phase I or Phase II in non-small cell lungcancer, gastric cancer, head and neck cancer, renal cancer, liver cancer and GIST.
Ilixadencel has potential in nearly every solid tumor due to the unique mechanism of action.
The unique immune enhancer ilixadencel has a clear potential to become a standard component in combination therapies in any cancer indication with injectable solid tumors. Therefore the stock potential is enormous. The mechanism of action of ilixadencel releases tumorspecific neoantigens and presents them for cytotoxic CD8+ T-cells which thus recognize tumor cells and can infiltrate the tumor (which they have proved in a Phase I/II-study).
Strong cash position USD 48 million.
Very promising Phase I/II renal cancer median survival data (2.7-2.8 years increased median survival).
Big trigger in Q3 when the Phase II study MERECA in renal cancer outcome will be official. If MERECA is successful the probabilty for success in other cancer indications also increases due to the versalite mechanism of action.
Market capital only USD 85 million due to a now completed (successful) diluting capital raize. (In Sweden there nearly always is a stock pullback when a capital raize is announced )
Immunicum is developing cancer-treating therapeutic candidates using a unique immuno-oncology approach. Their cell-based therapy is aimed at priming the patient’s immune system to attack and kill cancer cells. Immunicum’s lead candidate, ilixadencel,
Immunicum is developing cancer-treating therapeutic candidates using a unique immuno-oncology approach. Their cell-based therapy is aimed at priming the patient’s immune system to attack and kill cancer cells. Immunicum’s lead candidate, ilixadencel,
VD Carlos de Sousa presenterar bolaget Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare. Even...
VD Carlos de Sousa presenterar bolaget Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare. Even...
" Now, top pharma companies will be looking at the next wave of combinations of immunotherapies, in which ilixadencel is strongly positioned with a highly complementary mechanism of action, excellent safety profile and advanced stage of development, with over 90 patients already treated. We believe ilixadencel’s position as a potential backbone therapy to both targeted therapies and checkpoint inhibitors can take the center stage as the Phase II MERECA and Phase Ib/II ILIAD studies start reading out in 2019 and onwards."
http://www.biostock.se/sunday-interview-immunicum-ilixadencel-could-be-the-backbone-of-combination-therapies/
The Phase II MERECA study in renal cancer will be a great trigger in Q3 2019 when the results will become official. The Phase I/II-study (11 patients) in renal cancer was very promising with overall median survival 48 months with ilixadencel + standard treatment compared with 15-16 months according to the litterature with just standard treatment.
Immunicum will have a market capital of around USD 86 million after having completed the current stock issue, and with clinical studies completed or ongoing in Phase I or Phase II in non-small cell lungcancer, gastric cancer, head and neck cancer, renal cancer, liver cancer and GIST.
Ilixadencel has potential in nearly every solid tumor due to the unique mechanism of action.
A presentation of Immunicum : http://immunicum.se/wp-content/uploads/2018/11/IMMU-presentation-20181107-.pdf
Immunicum web site : http://immunicum.se/
https://www.biostock.se/2019/01/ceo-interview-immunicum-aims-to-take-immuno-oncology-to-new-heights/?fbclid=IwAR0-sUoQ0kacPCI5x0QI38b0fxpdyA0aErkr8VgI0_W61RA6vMdclfo4jFI
The unique immune enhancer ilixadencel has a clear potential to become a standard component in combination therapies in any cancer indication with injectable solid tumors.
Therefore the stock potential is enormous.
The mechanism of action of ilixadencel releases tumorspecific neoantigens and presents them for cytotoxic CD8+ T-cells which thus recognize tumor cells and can infiltrate the tumor (which they have proved in a Phase I/II-study).
Strong cash position USD 48 million.
Very promising Phase I/II renal cancer median survival data (2.7-2.8 years increased median survival).
Big trigger in Q3 when the Phase II study MERECA in renal cancer outcome will be official. If MERECA is successful the probabilty for success in other cancer indications also increases due to the versalite mechanism of action.
Market capital only USD 85 million due to a now completed (successful) diluting capital raize. (In Sweden there nearly always is a stock pullback when a capital raize is announced )
http://immunicum.se/